The FDA has granted approval for Roche’s PATHWAY HER2 (4B5) test to identify HER2-ultralow status in metastatic breast cancer patients, expanding its existing use for detecting HER2-low cases. This approval follows AstraZeneca and Daiichi Sankyo’s recent FDA clearance for Enhertu (trastuzumab deruxtecan) in HER2-ultralow patients, marking a significant advancement in breast cancer treatment. Enhertu is the first HER2-targeting antibody-drug conjugate (ADC) approved for patients with an immunohistochemistry (IHC) score of zero with faint staining in 10% or fewer tumor cells.
This systematic review and meta-analysis assessed the burden of micronutrient deficiencies among patients with type 2 diabetes (T2D), analyzing 132 studies with 52,501 participants. Micronutrient deficiencies in T2D were 45.30%, with vitamin D (60.45%), magnesium (41.95%), and B12 (28.72%) most common. Women were more affected.
The study provides a comprehensive analysis of diabetes trends among adolescents aged 10–24 years. Using data from the Global Burden of Disease (GBD) 2021 study, it estimates the prevalence, disability-adjusted life years (DALYs), and risk factors for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) across 204 countries and territories. The findings reveal a significant increase in the global burden of adolescent diabetes, with 3.4 million living with T1DM and 14.6 million with T2DM in 2021. By 2030, these numbers are projected to rise to 3.7 million and 20.9 million, respectively.
The study explores a potential preventive approach to radiation-induced otitis media with effusion (RIMOE), a common side effect in head and neck cancer patients undergoing radiotherapy. The researchers investigated whether dexamethasone (DEX) administration before radiation exposure could protect the middle ear and Eustachian tube from radiation damage.
The FDA has approved Novo Nordisk’s Ozempic to treat chronic kidney disease (CKD) in patients with Type 2 diabetes, expanding its role beyond diabetes management. Previously used primarily for blood sugar control and weight loss, Ozempic can now help slow kidney function decline, reduce the risk of kidney failure, and lower the chances of death from cardiovascular disease in these patients.
